• GSK published its Q3 2026 pipeline assets and clinical trials report.
• The pipeline includes 62 potential vaccines and medicines, with 21 in Phase III or registration.
• Felcorekibart for asthma advanced to Phase III; seasonal flu vaccine GSK4382276 also progressed to Phase III or registration.
• Jideytro delivered positive registrational data in treatment-naive patients with ROS1-positive non-small cell lung cancer.
• Efimosfermin alfa Phase III trials in compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis started in Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.